Could your genes predict a rare blood cancer? new study investigates

NCT ID NCT07204392

First seen Oct 31, 2025 · Last updated Jun 21, 2026 · Updated 30 times

Summary

This study aims to uncover inherited (germline) genetic factors that make some people more likely to develop myeloproliferative neoplasms (MPNs), a group of blood cancers. Researchers will analyze DNA from 313 patients diagnosed at a young age or with a family history of blood cancers. By identifying these genetic predispositions, the study hopes to improve understanding of why MPNs occur and who may be at higher risk.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fondazione IRCCS Policlinico San Matteo

    RECRUITING

    Pavia, Lombardy, 27100, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this research could identify inherited genetic markers that help predict who is at risk for these blood cancers, potentially leading to earlier monitoring or prevention strategies.

What could go wrong

This is an observational study, not a treatment trial. It may not find clear genetic links, and any findings would need further validation before affecting patient care.

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera cellular phase chronic idiopathic myelofibrosis essential thrombocythemia Myeloproliferative Disorders myeloproliferative neoplasm myeloproliferative neoplasm, unclassifiable primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.